Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 676

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 2
Chunk 676
---
The
Company’s former corporate headquarters was located in Baltimore, Maryland, which included a lease for office space. This lease
began in November 2022 and expired in April 2024. The lease was not renewed. The Company moved all corporate related activities in April
2024 to a shared office space in Tampa, Florida referenced footnote 5. In September 2024, the Company decided to no longer utilize the
shared space and moved to a virtual office model and does not have a physical office space as of December 31, 2024.

Item
3. Legal Proceedings.

None

Item
4. Mine Safety Disclosures.

Not
applicable.

46

PART
II

Item
5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market
Information

Our
common stock is listed on The Nasdaq Capital Market under the symbol “TELO” and began trading February 9, 2024.

Holders
of Common Stock

As
of February 4th, 2025, we had approximately 108 holders of record of our common stock. No cash dividends have been paid on the common
stock to date. A significant number of shares of our common stock are held in either nominee
name or street name brokerage accounts, and consequently, we are unable to determine the total number of beneficial owners of our common
stock.

Dividends

We have not paid any cash dividends
on our common stock to date and do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to
retain earnings, if any, for the future operation and expansion of our business. Any determination to pay cash dividends in the future
will be at the discretion of our board of directors and will depend upon our results of operations, cash requirements, financial condition,
contractual restrictions, restrictions imposed by applicable laws and other factors that our board of directors may deem relevant

Unregistered
Sales of Equity Securities and Use of Proceeds

We have previously disclosed all
sales of securities without registration under the Securities Act of 1933, as amended.

Issuer
Purchases of Equity Securities

None

Item
6. [Reserved]

47

Item
7.

MANAGEMENT’S
DISCUSSION AND ANALYSIS OF

FINANCIAL
CONDITION AND RESULTS OF OPERATIONS

The
following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of
our results of operations and financial condition.